How to Develop and Implement a National Drug Policy (Second Edition)
(2001; 96 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentContributors
View the documentAbbreviations and acronyms
View the documentPreface
Open this folder and view contentsPart I: How to develop and implement a national drug policy
Close this folderPart II: Key components of a national drug policy
Open this folder and view contents4. Selection of essential drugs
Open this folder and view contents5. Affordability
Open this folder and view contents6. Drug financing
Open this folder and view contents7. Supply systems
Close this folder8. Drug regulation
View the document8.1 Need for drug regulation and quality assurance
View the document8.2 Basic requirements for drug regulation
View the document8.3 Core elements of drug regulation
View the document8.4 Stepwise approach to drug registration
View the document8.5 Quality
View the document8.6 Safety
View the document8.7 Efficacy
View the document8.8 Information and drug promotion
View the document8.9 Information exchange with WHO and with other agencies
Open this folder and view contents9. Rational use of drugs
Open this folder and view contents10. Research
Open this folder and view contents11. Human resources development
Open this folder and view contents12. Monitoring and evaluation
View the documentReferences
View the documentSelected WHO publications and documents of related interest
View the documentBack cover

8.9 Information exchange with WHO and with other agencies

There are many ways in which drug regulatory authorities can exchange information between themselves or with international bodies such as WHO. These are some of the mechanisms:

Drug Safety Alerts: information issued by WHO in case of serious warnings on quality or safety. Also on

WHO Pharmaceutical Newsletter: a monthly newsletter issued by WHO with information on regulatory decisions by other regulatory agencies. Also on

WHO Drug Information: a quarterly publication with more general drug-related information, as well as reprints of important documents, such as the WHO Model List of Essential Drugs. Also on

UN Consolidated List of Products whose Consumption and/or Sale have been banned, withdrawn, severely restricted or not approved by Governments. Issued by the United Nations: this will be made available through the WHO web site:

WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce (see section 8.5): also on

WHODRA web site (with registered access):

United Nations Office for Drug Control and Crime Prevention (e.g. list of controlled drugs, international conventions):

Electronic discussion groups, such as E-drug: to subscribe contact: In text of message put subscribe e-drug (French and Spanish language versions also available). Also INDICES contact: In text of message put: Subscribe indices)

Examples of national web sites are:

South Africa:
Also: European Medicines Evaluation Agency:

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017